drugset / Trial / NCT02143856

Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food

NCT02143856

Phase 1 Completed 12 enrolled Lakefront Biotherapeutics NV
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to evaluate the amount of compound present in the blood (relative bioavailability) after a single oral administration of GLPG1205 given as a capsule formulation in fasted versus fed conditions in male healthy subjects. Also, the safety and tolerability of a single oral dose of GLPG1205 given as a capsule formulation under fasted and fed conditions will be assessed.

Timeline

Start
2014-05
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG1205 Small molecule 100 mg Oral

Indications

No indication recorded.